Business
Total Voting Rights
Convatec Group Plc has notified the market that as of December 31, 2025, its issued share capital consists of 2,049,789,559 ordinary shares, with 94,937,530 shares held in treasury, resulting in a total of 1,954,852,029 voting rights. This figure serves as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules. Disclaimer*
About this update from Convatec Group Plc
[{"type":"text","content":"\n\n2 January 2026\nConvatec Group Plc\n(\"Convatec\" or \"the Company\")\nTotal Voting Rights\nIn accordance with the UK Financial Conduct Authority's (\"FCA\") Disclosure and Transparency Rule 5.6.1R, the Company notifies the market that as at 31 December 2025:\n1. The Company's issued share capital comprised 2,049,789,559 ordinary shares of 10p each, each with one vote.\n2. 94,937,530 ordinary shares are held in treasury. These shares are not taken into consideration in relation to the payment of dividends and voting at shareholder meetings.\nAccordingly, the total number of voting rights in the Company is 1,954,852,029. This figure may be used by shareholders as the denominator for the calculations by which to determine if they are required to notify their interest in, or a change to, their interest in the Company under the FCA's Disclosure and Transparency Rules. \n \nContacts\n \nThe person responsible for making this announcement is James Kerton, Company Secretary, Convatec Group Plc: [email protected]\n \nMedia: [email protected]\n \nInvestor Relations: [email protected]\n \nConvatec Group Plc's LEI code is 213800LS272L4FIDOH92\n \nClassification: 2.5 Total number of voting rights and capital\n \nAbout Convatec \nPioneering trusted medical solutions to improve the lives we touch: Convatec is a global medical products and technologies company, focused on solutions for the management of chronic conditions, with leading positions in Advanced Wound Care, Ostomy Care, Continence Care, and Infusion Care. With more than 10,000 colleagues, we provide products and services in around 90 countries, united by a promise to be forever caring. Our solutions provide a range of benefits, from infection prevention, treatment for hard to heal wounds, at-risk skin and ulcerated tissue to supporting debilitating conditions, improved patient outcomes and reduced care costs. Convatec's revenues in 2024 were over $2 billion. The company is a constituent of the FTSE 100 Index (LSE:CTEC). To learn more please visit http://www.convatecgroup.com\n \n\n","length":3674,"tagName":"div"}]